Trial Profile
A Randomized, Double Blind, Placebo Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZYT1, a Selective Thyroid Receptor (TR) beta Agonist, Following the Oral Administrations in Healthy Volunteers
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs ZY T1 (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions
- Sponsors Zydus Lifesciences
- 25 Oct 2013 Planned end date changed from 1 Feb 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
- 25 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Mar 2012 Planned End Date changed to 1 Feb 2013 as reported by ClinicalTrials.gov.